Acitretin is an oral retinoid and the active metabolite of etidronate prescribed in dermatology. While most commonly used for the treatment of inflammatory disorders, its indications extend to disorders of keratinization in the paediatric population. In the midst of a safety announcement on isotretinoin side effects by the UK commission on Human Medicines, it is worth a debate whether acitretin monitoring should also be updated.